Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: Evaluation of 88 patients

International Journal of Gynecological Cancer

Volumn 18, Issue 6, 2008, Pages 1332-1338

  Park, J Y ^a   Kim, E N ^a   Kim, D Y ^a   Kim, J H ^a   Kim, Y M ^a   Kim, Y T ^a   Nam, J H ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Endometrial cancer; PET; PET CT; Surveillance

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 55949092628     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2008.01197.x     Document Type: Article

References (26)

1. Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994 55 : 229 33.
2. Owen P, Duncan ID. Is there any value in the long term follow up of women treated for endometrial cancer? Br J Obstet Gynaecol 1996 103 : 710 3.
3. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997 104 : 1302 7.
4. Kinkel K, Ariche M, Tardivon AA et al. Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging. Radiology 1997 204 : 55 63.
5. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000 95 : 692 6.
6. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999 40 : 1706 15.
7. Lai CH, Yen TC, Chang TC. Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol 2007 19 : 37 41.
8. Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002 29 : 1132 9.
9. Saga T, Higashi T, Ishimori T et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003 17 : 197 203.
10. Umesaki N, Tanaka T, Miyama M et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001 80 : 372 7.
11. Schoder H, Erdi YE, Larson SM, Yeung HW. PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003 30 : 1419 37.
12. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 2004 45 (Suppl. 1 82S 95S.
13. Sironi S, Picchio M, Landoni C et al. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2007 34 : 472 9.
14. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66.
15. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000 355 : 1404 11.
16. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001 6 : 47 86.
17. Burke TW, Heller PB, Woodward JE, Davidson SA, Hoskins WJ, Park RC. Treatment failure in endometrial carcinoma. Obstet Gynecol 1990 75 : 96 101.
18. Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991 40 : 55 65.
19. Benedet JL, Bender H, Jones H III., Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000 70 : 209 62.
20. Warburg O. The metabolism of tumors. London : Arnold Constable, 1930 : 75 327.
21. Nakahara T, Fujii H, Ide M et al. F-18 FDG uptake in endometrial cancer. Clin Nucl Med 2001 26 : 82 3.
22. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004 45 : 266 71.
23. Chao A, Chang TC, Ng KK et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006 33 : 36 44.
24. Horowitz NS, Dehdashti F, Herzog TJ et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004 95 : 546 51.
25. Suzuki R, Miyagi E, Takahashi N et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007 17 : 890 6.
26. Grigsby PW, Dehdashti F, Siegel BA. DFG-PET evaluation of recurrent endometiral carcinoma. 7th Biennial Meeting of the International Gynecologic Cancer Society, September 26-30, 1999; Rome, Italy.